Clinical Trials Directory

Trials / Terminated

TerminatedNCT01769547

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Ontario Clinical Oncology Group (OCOG) · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a single-arm, open label, two stage, phase II study of dovitinib in patients with advanced Malignant Pleural Mesothelioma (MPM). The primary purpose of this study is to evaluate the potential efficacy of dovitinib in the second- or third-line treatment of MPM using progression free survival (PFS).

Conditions

Interventions

TypeNameDescription
DRUGDovitinibTreatment continued until Disease Progression, Toxicity, or patient withdrawal.

Timeline

Start date
2013-03-01
Primary completion
2015-06-01
Completion
2015-06-01
First posted
2013-01-16
Last updated
2015-09-17

Locations

5 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT01769547. Inclusion in this directory is not an endorsement.